Description

Technical Parameters

Introduction

peptides

product-1400-1400

Products Description

### Systematic Analysis of Insulin-like Growth Factor 1 Long-acting Analog (IGF1-LR3)

#### Introduction

Insulin-like growth factor 1 (IGF1) is a key growth regulator that regulates cell proliferation, differentiation and metabolism by binding to receptors. However, the short half-life of natural IGF1 (about 10-12 hours) limits its application. As its long-acting analog, IGF1-LR3 significantly prolongs the duration of action through structural modification, becoming a research hotspot in the fields of medicine and sports science. This article will comprehensively analyze the characteristics of IGF1-LR3 from the perspectives of structure, physicochemical properties, biological activity to application areas.

### 1. Structural features and chemical modifications

The core advantage of IGF1-LR3 comes from its precise molecular design, including the following key modifications:

1. **Amino acid sequence extension**

- **N-terminal extension**: 13 amino acids (Arg-Arg-Ser-Arg-Arg-Arg-Glu-Ser) are added to the N-terminus of natural IGF1 to form an "extended arm", which enhances the interaction with binding proteins and reduces renal clearance.

- **E3R substitution**: Glutamic acid (Glu) at the third position is replaced by arginine (Arg) to improve the stability of the alkaline region.

2. **Molecular weight change**

- The molecular weight is about 9.1 kDa (natural IGF1 is 7.6 kDa), and the difference comes from amino acid extension and substitution.

3. **Three-dimensional structure retention**

- Circular dichroism (CD) analysis shows that its α-helix and β-folding structure are highly similar to natural IGF1, ensuring receptor binding activity.

### 2. Physicochemical properties

The physicochemical properties of IGF1-LR3 directly affect its preparation, storage and bioavailability:

1. **Solubility and stability**

- **Solubility**: Easily soluble in neutral or weakly acidic buffer (pH 6.0-7.4), low solubility in pure water (need to add 0.1% BSA or acetic acid to aid solubilization).

- **Thermal stability**: Stable storage for 7 days at 4°C, and active for more than 2 years in a freeze-dried state at -20°C. Repeated freezing and thawing can easily lead to aggregation.

- **pH sensitivity**: Extreme pH (<4 or >9) leads to irreversible denaturation, and strong acid/alkaline environments need to be avoided.

2. **Optical properties and color**

- **Solid-state**: High-purity products are white to off-white freeze-dried powders, and impurities (such as oxidation products) may cause a slight yellow color.

- **Solution state**: Colorless and transparent after dissolution, turbidity may indicate protein aggregation or contamination.

3. **Isoelectric point (pI)**

- The calculated pI is about 8.5 (native IGF1 is 8.0), which is attributed to the increase in arginine residues, which affects its behavior in ion exchange chromatography.

### 3. Biological activity and mechanism of action

IGF1-LR3 mediates downstream signaling pathways by activating the IGF1 receptor (IGF1R):

1. **Receptor affinity**

- The affinity for IGF1R (Kd≈1 nM) is comparable to that of natural IGF1, but the cross-reactivity to the insulin receptor (IR) is reduced, reducing side effects.

2. **Signaling pathway activation**

- **PI3K/AKT pathway**: Promotes glucose uptake and protein synthesis.

- **MAPK/ERK pathway**: Drives cell proliferation and differentiation, especially in muscle and chondrocytes.

3. **Pharmacokinetic advantages**

- Half-life is extended to 20-30 hours (natural IGF1 is 10 hours), and blood drug concentration can last for more than 48 hours after subcutaneous injection.

### 4. Application fields

The versatility of IGF1-LR3 makes it show potential in many fields:

1. **Medical research**

- **Muscle atrophy treatment**: Clinical trials have shown that it can increase the cross-sectional area of muscle fibers (such as cancer cachexia models).

- **Neuroprotection**: Promote neuronal survival and be used for dopaminergic neuron repair in Parkinson's disease models.

- **Wound healing**: Accelerate fibroblast migration and shorten the healing time of diabetic ulcers by 40%.

2. **Sports science**

- **Muscle-building effect**: Animal experiments have shown that muscle mass increases by 15%-20% after 4 weeks of injection, but the World Anti-Doping Agency (WADA) explicitly prohibits its use.

3. **Anti-aging research**

- **Skin regeneration**: Increase collagen synthesis and reduce wrinkle depth by activating dermal fibroblasts.

- **Metabolic regulation**: Improve insulin sensitivity in elderly individuals and reduce fasting blood sugar levels.

### 5. Preparation and storage

1. **Production method**

- **Recombinant DNA technology**: Commonly used E. coli expression system, high-purity product (>95%) obtained by inclusion body renaturation.

- **Purification process**: Combine ion exchange chromatography and gel filtration to remove endotoxin to <0.1 EU/mg.

2. **Storage conditions**

- **Lyophilized powder**: Store at -20℃ away from light, and it is recommended to use within 24 hours after reconstitution (store at 4℃).

- **Solution preparation**: It is recommended to use physiological saline containing 0.1% human serum albumin (HSA) to avoid repeated shaking.

### 6. Safety and regulatory status

1. **Potential risks**

- **Metabolic abnormalities**: Long-term high doses may cause hypoglycemia or insulin resistance.

- **Carcinogenicity**: In vitro studies suggest that it may promote the proliferation of certain cancer cells, which needs further verification.

2. **Legal supervision**

- **Medical use**: It has not been approved by the FDA or EMA and is limited to scientific research use.

- **Sports ban**: WADA has included it in the list of banned S2 peptide hormones, and athletes will face bans if they use it.

### Conclusion

IGF1-LR3 has achieved long-term activity through structural optimization and has broad prospects in the fields of medicine and scientific research. However, its application must strictly follow ethics and regulations, and future research should focus on safety evaluation and the development of targeted delivery systems to unlock its clinical translation potential.